AT A time when geopolitical tensions are hitting industries from semiconductors to electric vehicles, pharmaceutical ...

Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.

NKGen and its partners can begin to commercialize troculeucel in Korea, Japan and other markets where natural-killer ("NK”) cell therapy is already legal. NKGen proposal included up to $18 million in ...

Merus partners with Partner Therapeutics for U.S. rights to Zeno in NRG1+ cancer. Updated petosemtamab data emerge as a key ...

With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes ...

On Friday 29 November, the National Alternative Protein Innovation Centre (NAPIC) celebrated its highly anticipated formal ...

The breast cancer drug Enhertu will be added to China’s national health insurance scheme beginning in the new year — despite ...

The U.S. Food and Drug Administration gave SC291, a CD19-directed allogeneic CAR T cell therapy developed using Sana's hypoimmune platform, fast track designation, a process designed to facilitate the ...

After extending its review period to evaluate additional submissions, the FDA ultimately denied Applied Therapeutics’ ...

The weekly shop in Brazil is a little different these days, and may soon change in other parts of the world plagued by dengue ...

The FDA has rejected Applied Therapeutics’ attempt to win approval on the strength of a failed phase 3 trial, triggering a 75 ...

Yesintek, a monoclonal antibody, is approved for the treatment of Crohn's disease, olcerative colitis, plaque psoriasis, and ...